European CHMP recommends approval of glucagon (Ogluo)

Ogluo is a hybrid of of GlucaGen/GlucaGen Hypokit but is available as a ready-to-use formulation intended for subcutaneous injection and indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Source:

European Medicines Agency